4564.T Live signals | Maximize Profits with Getagraph.com

Live Chart Being Loaded With Signals

Commentary (24 Apr 2024 @ 02:15):

Stats
Today's Volume	2.60M
Average Volume	2.33M
Market Cap	4.14B
EPS	¥0 ( 2024-02-08 )
Next earnings date	( ¥0 ) 2024-05-09
Last Dividend	¥0 ( N/A )
Next Dividend	¥0 ( N/A )
P/E	-3.30
ATR14	¥0.150 (0.79%)

Volume Correlation

Long: -0.03 (neutral)

Short: 0.00 (neutral)

Signal:(48.083) Neutral

OncoTherapy Science, Inc. Correlation

10 Most Positive Correlations

10 Most Negative Correlations

Did You Know?

Correlation is a statistical measure that describes the relationship between two variables. It ranges from -1 to 1, where -1 indicates a perfect negative correlation (as one variable increases, the other decreases), 1 indicates a perfect positive correlation (as one variable increases, the other increases), and 0 indicates no correlation (there is no relationship between the variables).

Correlation can be used to analyze the relationship between any two variables, not just stocks. It's commonly used in fields such as finance, economics, psychology, and more.

OncoTherapy Science, Inc. Correlation - Currency/Commodity

-0.12
( neutral )

-0.07
( neutral )

0.00
( neutral )

-0.07
( neutral )

0.50
( neutral )

-0.06
( neutral )

OncoTherapy Science, Inc. Financials

Annual	2022
Revenue:	¥1.13B
Gross Profit:	¥41.69M (3.67 %)
EPS:	¥-5.81

Q3	2023
Revenue:	¥109.55M
Gross Profit:	¥-50.44M (-46.04 %)
EPS:	¥-1.270

Q2	2023
Revenue:	¥208.32M
Gross Profit:	¥-46.63M (-22.39 %)
EPS:	¥-1.450

Q1	2023
Revenue:	¥148.14M
Gross Profit:	¥-41.76M (-28.19 %)
EPS:	¥-1.990

Financial Reports:

No articles found.

OncoTherapy Science, Inc.

OncoTherapy Science, Inc. researches and develops anti-cancer medicines and therapies in Japan. Its clinical development product pipeline includes small-molecule drugs, such as OTS167, a maternal embryonic leucine zipper kinase inhibitor that is in Phase I/II clinical trials for the treatment of acute myeloid leukemia, as well as in Phase I clinical trials for the treatment of breast cancer; and OTS964, a T-LAK cell-originated protein kinase inhibitor for the treatment of various cancer diseases. The company's clinical development product pipeline also comprise cancer- specific peptide vaccines, including S-588410, which is in Phase III clinical trials for the treatment esophageal cancer, as well as in Phase II clinical trials for the treatment of bladder cancer; S-488210 that is in Phase I/II clinical trials for the treatment of head and neck cancer; and S-588210, which is in Phase I clinical trials for the treatment of solid tumor. In addition, it is developing antibody drugs consisting of OTSA101, which is in Phase I clinical trials for synovial sarcoma; and KHK6640, an anti-amyloid beta peptide antibody that is Phase I clinical trials for Alzheimer's disease. Further, the company provides contract analysis services. OncoTherapy Science, Inc. was founded in 2001 and is headquartered in Kawasaki, Japan.